Rare circulating cells

Major publications

• Circulating tumor cell copy-number heterogeneity in ALK-rearranged non-small-cell lung cancer resistant to ALK inhibitors. Oulhen M, Pawlikowska P, Tayoun T, Garonzi M, Buson G, Forcato C, Manaresi N, Aberlenc A, Mezquita L, Lecluse Y, Lavaud P, Naltet C, Planchard D, Besse B, Farace F. NPJ Precis Oncol. 2021 Jul 16;5(1):67. doi: 10.1038/s41698-021-00203-1.PMID: 34272470
• EPAC-lung: European pooled analysis of the prognostic value of circulating tumour cells in small cell lung cancer. Foy V, Lindsay CR, Carmel A, Fernandez-Gutierrez F, Krebs MG, Priest L, Carter M, Groen HJM, Hiltermann TJN, de Luca A, Farace F, Besse B, Terstappen L, Rossi E, Morabito A, Perrone F, Renehan A, Faivre-Finn C, Normanno N, Dive C, Blackhall F, Michiels S.Transl Lung Cancer Res. 2021 Apr;10(4):1653-1665. doi: 10.21037/tlcr-20-1061.PMID: 34012782
• Tumor Evolution and Therapeutic Choice Seen through a Prism of Circulating Tumor Cell Genomic Instability.Tayoun T, Oulhen M, Aberlenc A, Farace F, Pawlikowska P. Cells. 2021 Feb 5;10(2):337. doi: 10.3390/cells10020337.PMID: 33562741
• Proficiency Testing to Assess Technical Performance for CTC-Processing and Detection Methods in CANCER-ID. Neves RPL, Ammerlaan W, Andree KC, Bender S, Cayrefourcq L, Driemel C, Koch C, Luetke-Eversloh MV, Oulhen M, Rossi E, Alix-Panabières C, Betsou F, Farace F, Riethdorf S, Schlange T, Wikman H, Zamarchi R, Pantel K, Terstappen LWMM, Stoecklein NH; CANCER-ID Consortium. Clin Chem. 2021 Mar 31;67(4):631-641. doi: 10.1093/clinchem/hvaa322.PMID: 33491069
• V Faugeroux, E Pailler, M Oulhen, O Deas, L Brulle-Soumare, C Hervieu, V Marty, K Alexandrova, KC Andree, N H Stoecklein, D Tramalloni, ScCairo, M NgoCamus, C Nicotra, LWMM Terstappen^, N Manaresi, V Lapierre, K Fizazi, JY Scoazec^, Y Loriot, JG Judde, F Farace. Genetic characterization of a Unique Neuroendocrine Transdifferentiation Prostate Circulating Tumor Cell - Derived eXplant Model. Nature Com 2020 Apr 20;11(1):1884. doi: 10.1038/s41467-020-15426-2.
• SFCE-RAPIRI Phase I Study of Rapamycin Plus Irinotecan: A New Way to Target Intra-Tumor Hypoxia in Pediatric Refractory Cancers. Jannier S, Kemmel V, Sebastia Sancho C, Chammas A, Sabo AN, Pencreach E, Farace F, Chenard MP, Lhermitte B, Geoerger B, Aerts I, Frappaz D, Leblond P, André N, Ducassou S, Corradini N, Bertozzi AI, Guérin E, Vincent F, Velten M, Entz-Werle N. Cancers (Basel). 2020 Oct 20;12(10):3051. doi: 10.3390/cancers12103051.PMID: 33092063
• Exploitation of the chick embryo chorioallantoic membrane (CAM) as a platform for anti-metastatic drug testing. Pawlikowska P, Tayoun T, Oulhen M, Faugeroux V, Rouffiac V, Aberlenc A, Pommier AL, Honore A, Marty V, Bawa O, Lacroix L, Scoazec JY, Chauchereau A, Laplace-Builhe C, Farace F. Sci Rep. 2020 Oct 9;10(1):16876. doi: 10.1038/s41598-020-73632-w.PMID: 33037240
• Pailler E, Faugeroux V, Oulhen M, Mezquita L, Laporte M, Honoré A, Lecluse Y, Queffelec P, NgoCamus M, Nicotra C, Remon J, Lacroix L, Planchard D, Friboulet L, Besse B, Farace F. Acquired Resistance Mutations to ALK Inhibitors Identified by Single Circulating Tumor Cell Sequencing in ALK-Rearranged Non-Small-Cell Lung Cancer. Clin Cancer Res. 2019 Aug 22. doi: 10.1158/1078-0432.CCR-19-1176.
• Faugeroux V, Lefebvre C, Pailler E, Pierron V, Marcaillou C, Tourlet S, Billiot F, Dogan S, Oulhen M, Vielh P, Rameau P, NgoCamus M, Massard C, Laplace-Builhé C, Tibbe A, Taylor M, Soria J-C, Fizazi K, Loriot Y, Julien S and Farace F. An Accessible and Unique Insight into Metastasis Mutational Content through Whole-Exome Sequencing of Circulating Tumor Cells in Metastatic Prostate Cancer”. Eur Urol Oncol 2019, Jan 4. pii: S2588-9311(18)30213-X. doi: 10.1016/j.euo.2018.12.005.
• Tayoun T, Faugeroux V, Oulhen M, Aberlenc A, Pawlikowska P, Farace F. CTC-Derived Models: A Window into the Seeding Capacity of Circulating Tumor Cells (CTCs). Cells 2019 Sep 25;8(10). pii: E1145. doi: 10.3390/cells8101145. Review.
• Pawlikowska P, Faugeroux V, Oulhen M, Aberlenc A, Tayoun T, Pailler E, Farace F, Circulating tumor cells (CTCs) for the noninvasive monitoring and personalization of non-small cell lung cancer (NSCLC) therapies. J Thorac Dis 2019;11(Suppl 1):S45-S56; doi: 10.21037/jtd.2018.12.80. Review.
• Lindsay CR, Blackhall FH, Carmel A, Fernandez-Gutierrez F, Gazzaniga P, Groen HJM, Hiltermann TJN, Krebs MG, Loges S, López-López R, Muinelo-Romay L, Pantel K, Priest L, Riethdorf S, Rossi E, Terstappen L, Wikman H, Soria JC, Farace F, Renehan A, Dive C, Besse B, Michiels S. EPAC-lung: pooled analysis of circulating tumour cells in advanced non-small cell lung cancer. Eur J Cancer. 2019 Aug;117:60-68. doi: 10.1016/j.ejca.2019.04.019. Epub 2019 Jun 27.
• de Wit S, Manicone M, Rossi E, Lampignano R, Yang L, Zill B, Rengel-Puertas A, Ouhlen M, Crespo M, Berghuis AMS, Andree KC, Vidotto R, Trapp EK, Tzschaschel M, Colomba E, Fowler G, Flohr P, Rescigno P, Fontes MS, Zamarchi R, Fehm T, Neubauer H, Rack B, Alunni-Fabbroni M, Farace F, De Bono J, IJzerman MJ, Terstappen LWMM.  EpCAM(high) and EpCAM(low) circulating tumor cells in metastatic prostate and breast cancer patients. Oncotarget. 2018 Nov 2;9(86):35705-35716. doi:10.18632/oncotarget.26298.
• Andree KC, Mentink A, Zeune LL, Terstappen LWMM, Stoecklein NH, Neves RP,Driemel C, Lampignano R, Yang L, Neubauer H, Fehm T, Fischer JC, Rossi E, Manicone M, Basso U, Marson P, Zamarchi R, Loriot Y, Lapierre V, Faugeroux V, Oulhen M, Farace F, Fowler G, Sousa Fontes M, Ebbs B, Lambros M, Crespo M, Flohr P, de Bono JS. Toward a real liquid biopsy in metastatic breast and prostate cancer: Diagnostic LeukApheresis increases CTC yields in a European prospective multicenter study (CTCTrap). Int J Cancer. 2018 Nov 15;143(10):2584-2591. 
• Massard C, Borget I, Farace F, Aspeslagh S, Le Deley MC, Le Tourneau C, Bidard FC, Pierga JY, Dieras V, Hofman P, Spano JP, Ferte C, Lacroix L, Soria JC. RECIST response and variation of circulating tumour cells in phase 1 trials: A prospective multicentric study. Eur J Cancer. 2017 Sep;83:185-193.